Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

(2015) Tobias Derfuss et al.   JOURNAL OF NEUROIMMUNOLOGY

Promoting remyelination in multiple sclerosis: Current drugs and future prospects

(2015) David Kremer et al.   Multiple Sclerosis Journal

Promoting remyelination in multiple sclerosis: Current drugs and future prospects

(2015) David Kremer et al.   Multiple Sclerosis Journal

Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process

(2014) M Bonora et al.   CELL DEATH AND DIFFERENTIATION

Rheumatoid Arthritis is Associated with IgG Antibodies to Human Endogenous Retrovirus Gag Matrix: A Potential Pathogenic Mechanism of Disease?

(2014) P. N. Nelson et al.   JOURNAL OF RHEUMATOLOGY

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

(2014) François Curtin et al.   mAbs

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status

(2014) Violaine K. Harris et al.   Molecular Diagnosis & Therapy

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

(2014) Tobias Derfuss et al.   Multiple Sclerosis Journal

The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade

(2014) David Kremer et al.   Multiple Sclerosis Journal

The enemy within: endogenous retroelements and autoimmune disease

(2014) Hannah E Volkman et al.   NATURE IMMUNOLOGY

Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation

(2013) David Kremer et al.   ANNALS OF NEUROLOGY

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

(2013) P. S. Rommer et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Personalized Medicine in Neurodegenerative Diseases: How Far Away?

(2013) Kristina Gotovac et al.   Molecular Diagnosis & Therapy

Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study

(2013) Giannina Arru et al.   Multiple Sclerosis Journal

The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity

(2013) Marta Garcia-Montojo et al.   PLoS One

Human Endogenous Retrovirus Protein Activates Innate Immunity and Promotes Experimental Allergic Encephalomyelitis in Mice

(2013) Hervé Perron et al.   PLoS One

Novel therapeutic options for multiple sclerosis

(2013) François Curtin et al.   Expert Review of Clinical Pharmacology

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

(2012) François Curtin et al.   CLINICAL THERAPEUTICS

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease

(2012) Hervé Perron et al.   Multiple Sclerosis Journal

Endogenous viruses: insights into viral evolution and impact on host biology

(2012) Cédric Feschotte et al.   NATURE REVIEWS GENETICS

Remyelination Therapy for Multiple Sclerosis

(2012) Michael B. Keough et al.   Neurotherapeutics

Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder

(2012) H Perron et al.   Translational Psychiatry

Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis

(2010) Renée Douville et al.   ANNALS OF NEUROLOGY

Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis

(2010) S. Sotgiu et al.   Multiple Sclerosis Journal

Recent developments in multiple sclerosis therapeutics

(2009) Rebecca I Spain et al.   BMC Medicine

The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation

(2009) Hervé Perron et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Infections and autoimmunity: the multifaceted relationship

(2009) P. Sfriso et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA from patients with multiple sclerosis

(2009) Giuseppe Mameli et al.   JOURNAL OF VIROLOGICAL METHODS

Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis

(2009) M Saresella et al.   Multiple Sclerosis Journal

Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE

(2008) Andras Perl et al.   AUTOIMMUNITY

Inhibition of multiple sclerosis–associated retrovirus as biomarker of interferon therapy

(2008) Giuseppe Mameli et al.   JOURNAL OF NEUROVIROLOGY

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

(2008) R. Aharoni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA